
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 24, 2025

OraSure Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-16537
(Commission
File Number)

36-4370966
(I.R.S. Employer
Identification No.)

**220 East First Street
Bethlehem, Pennsylvania**
(Address of Principal Executive Offices)

18015-1360
(Zip Code)

Registrant's telephone number, including area code: 610-882-1820

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.000001 par value per share	OSUR	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by a check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On March 24, 2025, OraSure Technologies, Inc. issued a press release announcing the authorization and approval, by the Company's board of directors (the "Board") on March 21, 2025, of a stock repurchase program for up to \$40 million of shares of the Company's common stock, par value \$0.000001 per share ("Common Stock") for a period of two years (the "Stock Repurchase Plan"). Concurrently with such authorization and approval, the Company terminated the existing repurchase program, which was implemented by the Board on August 5, 2008. Under the Stock Repurchase Plan, the Company intends to repurchase shares through open market purchases, privately-negotiated transactions, block purchases or otherwise in accordance with applicable federal securities laws.

The Board also authorized the Company to enter into a written repurchase plan under Rule 10b5-1 and 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The actual timing, manner, number, and value of shares repurchased under the Stock Repurchase Plan will be determined by the Company at its discretion and will depend on several factors, including constraints specified in the trading plan, price, general business and market conditions, and alternative investment opportunities. Information regarding share repurchases will be available in the Company's periodic reports on Form 10-Q and 10-K filed with the Securities and Exchange Commission ("SEC") as required by the applicable rules of the Exchange Act.

This Stock Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock and the program may be extended, modified, suspended or discontinued at any time at the Company's discretion.

Forward Looking Statements

This Current Report contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to the Stock Repurchase Plan and the factors that will impact the amount and timing of purchases, if any, thereunder. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to, changes in price and volume and the volatility of the Common Stock and the other risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's subsequent filings with the SEC. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release, dated March 24, 2025, announcing authorization and approval of stock repurchase program.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: March 24, 2025

By: /s/ Carrie Eglinton Manner
Carrie Eglinton Manner
President and Chief Executive Officer



OraSure Technologies, Inc.

EXHIBIT 99.1

Investor Contact:
Jason Plagman
VP, Investor Relations
investorinfo@orasure.com

Media Contact:
Amy Koch
Director, Corporate Communications
media@orasure.com

OraSure Announces \$40 Million Stock Repurchase Program

BETHLEHEM, PA, March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the "Company") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to \$40 million of its common stock over the next twenty-four months, which will be funded from cash on hand.

The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. The amount and timing of share repurchases will be determined by Management at its discretion. The repurchase program may be modified, suspended, or discontinued at any time at the Company's discretion without prior notice.

About OraSure Technologies, Inc.

OraSure Technologies, Inc. ("OraSure") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure, please visit www.orasure.com.

Forward Looking Statements

This Press Release contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to the Stock Repurchase Plan and the factors that will impact the amount and timing of purchases, if any, thereunder. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to, changes in price and volume and the volatility of the Common Stock and the other risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's subsequent filings with the SEC. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

###